CDK4 and breast cancer: This review highlights how innovative approaches like targeting intratumoral heterogeneity, liquid biopsy for resistance mutation detection, bypass mechanisms (FGFR1 activation following CDK4/6 inhibition), artificial intelligence‐based drug discovery, patient‐derived organoids, and adaptive trial designs are shaping BC treatment.